Clinical Trial

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06355037
Lead Sponsor Fudan University
Conditions Triple-negative Breast Cancer
Enrollment 10 participants
Start Date 2024-05-20
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-08